LAYQETA
Live / Applied — Suspended — suspension letter mailed (as of 11 Feb 2026)
What this means for you
Not registered yet, but its 06 Feb 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99637935
- Mark type
- Stylized text
- Filed
- 06 Feb 2026
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of damaged skin and tissue, pain, inflammation, obesity, and infectious diseases; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, hematological, bacterial, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; Pharmaceutical preparations for the prevention of infectious diseases; Vaccines; Anti-infectives
Owner
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 11 Feb 2026 — NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
- 11 Feb 2026 — LETTER OF SUSPENSION E-MAILED
- 11 Feb 2026 — SUSPENSION LETTER WRITTEN
- 10 Feb 2026 — ASSIGNED TO EXAMINER
- 06 Feb 2026 — APPLICATION FILING RECEIPT MAILED
- 06 Feb 2026 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 06 Feb 2026 — NEW APPLICATION ENTERED